1. Aprotinin in primary valve replacement and reconstruction: A multicenter, double-blind, placebo-controlled trial 
Michael N. D'Ambra, MD, Cary W. Akins, MD, Eugene H. Blackstone, MD, Sharon L. Bonney, MD, Lawrence H. Cohn, MD, Delos M. Cosgrove, MD, Jerrold H. Levy, MD, Karen E. Lynch, BSN, Rosemarie Maddi, MD 
The Journal of Thoracic and Cardiovascular Surgery 
Volume 112, Issue 4, Pages (October 1996)
DOI: /S (96)
Copyright © 1996 Mosby, Inc. Terms and Conditions

2. Fig. 1
The intraoperative rate of transfusion for patients treated with high-dose aprotinin was significantly higher than the rate of transfusion for patients in the low-dose aprotinin and placebo treatment groups (p = 0.03). This difference did not continue into the postoperative period (p > 0.05). POD, Postoperative day.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) )
Copyright © 1996 Mosby, Inc. Terms and Conditions

3. Fig. 2
Mediastinal drainage was not a predictor of the number of allogeneic red blood cells required in the high-dose aprotinin group. The different bars represent the number of units transfused.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) )
Copyright © 1996 Mosby, Inc. Terms and Conditions

4. Fig. 3
Changes in serum creatinine concentration of ≥0.5 mg/dl occurred significantly more often in the aprotinin-treated group (p = 0.003). This difference did not persist for a change in creatinine of >2 mg/dl. Creat, Creatinine.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /S (96) )
Copyright © 1996 Mosby, Inc. Terms and Conditions